CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today released its 2024 Corporate Sustainability Report entitled Progress Takes Shape. Aptar's report highlights key milestones of its global sustainability strategy across the company's global operations focused on three key pillars: Care - operating with care for employees, communities and the environment by aiming to continuously impr.
Invest in stocks of MVST, SBS, CARG and ATR to tap their high-efficiency levels.
ATR gains from its business transformation plan and healthy segmental performance.
Here is how AptarGroup (ATR) and Epiroc Aktiebolag Unsponsored ADR (EPOKY) have performed compared to their sector so far this year.
AptarGroup (ATR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
AptarGroup (ATR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ATR estimates second-quarter 2024 adjusted earnings per share of $1.56-$1.64.
AptarGroup (ATR) possesses solid growth attributes, which could help it handily outperform the market.
AptarGroup, Inc. (NYSE:ATR ) Q1 2025 Earnings Conference Call May 2, 2025 9:00 AM ET Company Participants Mary Skafidas - Senior Vice President, Investor Relations & Communications Stephan Tanda - President & Chief Executive Officer Vanessa Kanu - Executive Vice President & Chief Financial Officer Conference Call Participants George Staphos - Bank of America Ghansham Panjabi - Baird Matt Roberts - Raymond James Daniel Rizzo - Jefferies Matt Larew - William Blair Gabe Hajde - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. Welcome to Aptar's 2025 First Quarter Results Conference Call.
AptarGroup (ATR) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports First Quarter 2025 Results.
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies